Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/26341| Title: | Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy. | Austin Authors: | Klein, Oliver ;Kee, Damien ;Markman, Ben;Carlino, Matteo S;Underhill, Craig;Palmer, Jodie ;Power, Daniel;Cebon, Jonathan S ;Behren, Andreas | Affiliation: | Albury-Wodonga Regional Cancer Centre, Albury-Wodonga, Australia Monash University, Melbourne, Australia Department of Medical Oncology, Alfred Health, Melbourne, Australia Olivia Newton-John Cancer Research Institute Blacktown Hospital and the University of Sydney, Sydney, Australia Department of Medical Oncology, Peter McCallum Cancer Centre, Melbourne, Australia Medical Oncology School of Cancer Medicine, La Trobe University, Australia ThermoFisher Scientific Ltd |
Issue Date: | 29-Apr-2021 | Date: | 2021-05-10 | Publication information: | Cancer Cell 2021; 39(5): 592-593 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/26341 | DOI: | 10.1016/j.ccell.2021.04.005 | Journal: | Cancer Cell | PubMed URL: | 33930312 | Type: | Journal Article |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.